Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853328 | 0.91 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL23530252 | 0.88 | CSNK2A1 (0.37) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL30918942 | 0.87 | CSNK2A1 (0.37) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL8326067 | 0.87 | MAPT (0.42) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL4207156 | 0.86 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL8325968 | 0.85 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL4253521 | 0.84 | EGFR (0.40) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL2492487 | 0.82 | FGFR4 (0.40) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL12405455 | 0.81 | CSNK2A1 (0.40) | CSNK2A1CSNK2A2USP30GRM5EGFR | |
| SCHEMBL4928378 | 0.81 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2USP30GRM5EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949578-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | CSNK2A1 1382/4885CSNK2A2 1608/4885USP30 3440/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | CSNK2A1 1066/4885CSNK2A2 1233/4885USP30 3866/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | CSNK2A1 1257/4885CSNK2A2 1441/4885USP30 3782/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | CSNK2A1 1257/4885CSNK2A2 1441/4885USP30 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.